Free Trial
NASDAQ:SNOA

Sonoma Pharmaceuticals 8/7/2025 Earnings Report

Sonoma Pharmaceuticals logo
$1.15 -0.03 (-2.54%)
Closing price 05/13/2026 04:00 PM Eastern
Extended Trading
$1.15 0.00 (0.00%)
As of 07:39 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Sonoma Pharmaceuticals EPS Results

Actual EPS
-$0.37
Consensus EPS
-$0.51
Beat/Miss
Beat by +$0.14
One Year Ago EPS
N/A

Sonoma Pharmaceuticals Revenue Results

Actual Revenue
$4.01 million
Expected Revenue
$4.26 million
Beat/Miss
Missed by -$250.00 thousand
YoY Revenue Growth
N/A

Sonoma Pharmaceuticals Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Sonoma Pharmaceuticals' next earnings date is estimated for Wednesday, July 15, 2026, based on past reporting schedules.

Conference Call Resources

Sonoma Pharmaceuticals Earnings Headlines

From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the biggest story of his 26-year career - an economic shift not seen since 1776. From the government taking stakes in Intel, Lithium Americas, and MP Materials, to sweeping political changes reshaping the economy, Stansberry argues a rare 'New 1776 Moment' is already underway. One Nobel Prize winner calls it a dividing line for all of society. His presentation covers the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.tc pixel
See More Sonoma Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sonoma Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sonoma Pharmaceuticals and other key companies, straight to your email.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals (NASDAQ:SNOA) is a specialty dermatology company focused on developing and commercializing topical prescription and over-the-counter products for inflammatory and infectious skin conditions. Publicly traded on Nasdaq under the symbol SNOA, the company concentrates its efforts on areas such as acne, rosacea, dermatitis and wound care, aiming to provide physicians and patients with innovative treatment options.

At the heart of Sonoma’s technology platform lies its proprietary Triphasic drug delivery system, which enables the timed release of active ingredients through three distinct gel phases. This approach is designed to enhance efficacy while minimizing skin irritation. The company’s lead product, Azclear® Foaming Gel, leverages azelaic acid to address papulopustular rosacea, and is complemented by additional prescription formulations and a suite of over-the-counter cleansers and medicated washes targeting acne-prone skin.

Headquartered in Santa Rosa, California, Sonoma Pharmaceuticals distributes its dermatology portfolio through physician offices, retail pharmacies and online channels across the United States. Under the leadership of President and Chief Executive Officer Mark D. Sirgo, the company is advancing its clinical pipeline and exploring strategic collaborations to expand its product offerings and reach new patient populations.

View Sonoma Pharmaceuticals Profile